Poland questions stand-alone nurse-led chronic wound care in its current design.
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.social
@abangelabs.bsky.socialPoland questions stand-alone nurse-led chronic wound care in its current design.
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialLong-term follow-up strengthens the value case for outpatient labour induction.
#HTA #HealthEconomics #RWE
@abangelabs.bsky.socialSpecialised formula access expands for pyridoxine-dependent epilepsy.
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialAOTMiT recommends against Akeega reimbursement in metastatic prostate cancer, citing comparator uncertainty. https://www.mattheneus.com/editorial/aotmit-akeega-mhspc-negative-reimbursement-amplitude-comparator-uncertainty-2026-09-29 #HTA #HealthEconomics
@abangelabs.bsky.socialFrance grants early access to first-line Braftovi in metastatic colorectal cancer, focusing attention on evidence for access decisions. https://www.mattheneus.com/editorial/has-braftovi-first-line-metastatic-colorectal-early-access-breakwater-2026-09-23 #HTA #Pharma
@abangelabs.bsky.socialGoal Attainment Scaling needs a documented implementation record before it can support credible payer evidence. https://www.mattheneus.com/editorial/goal-attainment-scaling-implementation-record-payer-evidence-2026-10-04 #HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialAI screening for retinopathy of prematurity kept its modelled value until rural coverage fell to 11%, exposing a critical implementation threshold. https://www.mattheneus.com/editorial/ai-retinopathy-prematurity-screening-rural-coverage-cost-effectiveness-2026-10-02 #HTA #HealthEconomics #RWE
@abangelabs.bsky.socialAustralia grants brivaracetam oral solution a formulation-specific pricing exemption, separating its pricing treatment from other forms. https://www.mattheneus.com/editorial/pbac-brivaracetam-oral-solution-section84ah-price-exemption-2026-10-01 #HTA #Pharma #HealthEconomics
@abangelabs.bsky.socialAustralia expands access to metabolic formulas for ECHS1 and HIBCH deficiencies, widening support for two rare disorders. https://www.mattheneus.com/editorial/pbac-echs1-hibch-metabolic-formula-listing-extension-2026-07 #HTA #HealthEconomics #Pharma
@abangelabs.bsky.socialGermany's proposed evidence-potential route could reshape how high-need medicines enter AMNOG assessment. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/g-ba-amnog-reform-qualitative-potential-evidence-route-2026-09-23
@abangelabs.bsky.socialNew MHRA guidance sharpens how periodic safety reports are routed and followed up in the UK. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/mhra-psur-routing-eurd-psusa-pharmacovigilance-guidance-2026-09-30
@abangelabs.bsky.socialNICE moves fourth-line isatuximab into routine myeloma care, with SACT data shaping the comparator story. https://www.mattheneus.com/editorial/nice-ta1194-isatuximab-fourth-line-myeloma-sact-comparator-2026-09-24 #HTA #HealthEconomics #RWE
@abangelabs.bsky.socialGermany and Switzerland place cybersecurity responsibility at different points in digital-health reimbursement. https://www.mattheneus.com/editorial/digital-health-cybersecurity-reimbursement-responsibility-germany-switzerland-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs
@abangelabs.bsky.socialEMA has set the next CTIS build priorities around the Biotech Act and accelerated assessment. https://www.mattheneus.com/editorial/ema-ctis-biotech-act-accelerated-assessment-modernisation-2026-10-01 #HTA #RegulatoryAffairs #Pharma
@abangelabs.bsky.socialUniversal malaria testing could save the US blood supply $13.6M in year one. https://www.mattheneus.com/editorial/universal-malaria-nat-screening-us-blood-supply-budget-impact-2026-10-01 #HTA #HealthEconomics #RWE
@abangelabs.bsky.socialGermany finalizes the legacy combination-discount register following statutory repeal. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/g-ba-annex-xiia-combination-discount-final-validity-register-2026-10-01
@abangelabs.bsky.socialAnchored MAIC connects tralokinumab and dupilumab evidence in hand atopic dermatitis. #HTA #MAIC #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/pubmed-tralokinumab-dupilumab-hand-atopic-dermatitis-anchored-maic-2026-10-02
@abangelabs.bsky.socialGermany has opened a comparative routine-care evidence procedure for nadofaragene in bladder cancer, putting real-world evidence design in focus. https://www.mattheneus.com/editorial/g-ba-nadofaragene-bladder-cancer-real-world-evidence-collection-procedure-2026-10-01 #HTA #RWE
@abangelabs.bsky.socialA Saudi model puts pembrolizumab for cervical cancer near the cost-effectiveness threshold, sharpening the local value question. https://www.mattheneus.com/editorial/pubmed-pembrolizumab-cervical-cancer-saudi-cost-effectiveness-keynote-a18-2026-10-02 #HTA #HealthEconomics
@abangelabs.bsky.socialProject Orbis cases reveal where faster Canadian regulatory review still leaves a critical HTA and access handoff. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/project-orbis-canada-regulatory-hta-access-handoff-2026-10-02